Meet Shiao-Pei Weathers, M.D.
Shiao-Pei Weathers, M.D.
Department of Neuro-Oncology, Division of Cancer Medicine
About Dr. Weathers
Dr. Shiao-Pei Weathers is an Associate Professor in the Department of Neuro-Oncology who specializes in primary brain tumors, specifically gliomas. She obtained her medical degree from Wright State University Boonshoft School of Medicine. She then went on to complete an internship at St. Joseph Hospital, neurology residency at the University of Michigan, and a clinical fellowship in neuro-oncology at MD Anderson Cancer Center. Dr. Weathers joined the MD Anderson neuro-oncology faculty in 2015. She has served as PI or co-investigator on numerous clinical trials for patients with newly diagnosed glioblastoma or recurrent glioblastoma, and is actively involved in devising new treatment strategies and combinations for these patient groups. Dr. Weathers also collaborates on research to develop multi-disciplinary treatment approaches for improving the survival and quality-of-life of glioma patients. She serves as Director of the MD Anderson Neuro-Oncology Fellowship Program, Director of the MD Anderson Brain tumor Education and Support Together (BEST) group to educate and counsel primary brain tumor patients and their caregivers.
Present Title & Affiliation
Primary Appointment
Section Chief, Brain Tumor Section, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Center Medical Director, Brain and Spine Center, The University of Texas MD Anderson Cancer Center, Houston, TX
Fellowship Program Director, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Wright State University Boonshoft School of Medicine, Dayton, Ohio, US, Medicine, MD |
| 2005 | University of Notre Dame, Notre Dame, Indiana, US, Psychology, BA |
Postgraduate Training
| 2013-2014 | Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2012-2013 | Chief Resident, Neurology, University of Michigan, Ann Arbor, Michigan |
| 2010-2013 | Clinical Residency, Neurology, University of Michigan, Ann Arbor, Michigan |
| 2009-2010 | Clinical Internship, Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, Michigan |
Licenses & Certifications
| 2017 | United Council for Neurologic Subspecialties |
| 2014 | Texas Medical License |
| 2013 | American Board of Psychiatry and Neurology |
| 2013 | Michigan Medical License |
Experience & Service
Administrative Appointments/Responsibilities
Section Chief, Brain Tumor Section, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Patient Experience Officer, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Center Medical Director, Brain and Spine Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Fellowship Program Director, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Extramural Institutional Committee Activities
Member, Cancer Neuroscience Program Neuro Neoplasms Steering Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Access Medical Core Team, Chaired by Dr. Randy Weber and Dr. Amy Hassan, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, BTC Emerging Leader Symposium Organizing Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Brain Tumor Center Emerging Leader Symposium Organizing Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Handoff Communication I-PASS Taskforce, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Brain Tumor Center Tissue Utilization Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Brain Tumor Center Executive Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Participant, MD Anderson Leadership Institute, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Brain and Spine Center Patient Experience Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Graduate Medical Education Committee (GMEC), The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Hematology-Oncology Fellowship Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, GME Curriculum Subcommittee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, Neuro-Oncology Fellowship Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Honors & Awards
| 2023 | Finalist, Irwin Karloff Award for Excellence in Clinical Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2021 - 2022 | A top 10% provider for MD Anderson in FY22, The University of Texas MD Anderson Cancer Center |
| 2021 | Finalist, Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2020 - 2021 | A top 1% provider for MD Anderson in FY21, The University of Texas MD Anderson Cancer Center |
| 2020 | Finalist, Irwin Karloff Award for Excellence in Clinical Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2019 | Finalist, Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2013 | Golden Beeper Award, University of Michigan |
| 2013 | Status Pedagogicus in Situ Award, University of Michigan |
| 2013 | Neuroscience Day Platform Presentation Winner, University of Michigan |
| 2012 | Making a Difference Award, University of Michigan |
| 2012 | Neuroscience Day Platform Presentation, University of Michigan |
| 2009 - 2010 | St. Joseph Mercy Preliminary Medicine Intern of the Year, St. Joseph Mercy Hospital |
| 2008 | Gold Humanism Honor Society Wright State Chapter, Wright State University Boonshoft School of Medicine |
| 2006 | AHEC Search Project Honorable Mention, State of Ohio |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Primary CNS Tumors. Invited. Neurology Grand Rounds. Houston, TX, US.
- 2026. Neuro-Oncology 101: What Every Neurology Resident Should Know. Invited. Neurology Grand Rounds. Brooklyn, New York, US.
- 2025. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2025. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2023. Advancing Clinical Trial Design in Glioblastoma. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2022. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2022. Baseline Tumor Genomic and Gut Microbiota Association with Clinical Outcomes in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. Baseline Tumor Genomic and Gut Microbiota Association with Clinical Outcomes in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. Baseline Tumor Genomic and Gut Microbiota Association with Clinical Outcomes in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2020. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2019. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2019. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2019. Transformative Clinical Trials for the Treatment of Glioblastoma: The CMV and Delta-24-RGD Stories. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2017. A Case Based Critical Thinking Exercise in Neuro-Oncology. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2016. Long-term survivors and of pregnancy and glioma (poster presentation). Conference. MDACC and The Duncan Family Institute. Houston, TX, US.
- 2015. CNS Lymphoma. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
National Presentations
- 2023. WEBINAR SPEAKER: Understanding Clinical Trials and Improving Access. Invited. American Brain Tumor Association (ABTA), US.
- 2022. ORAL PRESENTER: Baseline Tumor Genomic and Gut Microbiota Association with Clinical Outcomes in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Invited. American Society of Clinical Oncology. Chicago, IL, US.
- 2021. PRESENTER: Support Groups and Education. Invited. Society for Neuro-Oncology, 2021 Education Day. Boston, MA, US.
- 2020. PRESENTER: Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Invited. American Society of Clinical Oncology. Chicago, IL, US.
- 2020. PRESENTER: A Phase I/II Clinical Trial of Autologous CMV-specific T Cells in Glioblastoma (GBM) Patients to Reveal a Lack of Immune Effector Function. Invited. American Society of Clinical Oncology. Chicago, IL, US.
- 2019. ETALK: (QOLP) Acceptability Randomized Controlled Trial a Couples-Based Mind-Body Intervention for Patients with High Grade Glioma and their Partners. Invited. Society for Neuro-Oncology. Phoenix, AZ, US.
- 2018. ETALK: (ATIM-37) Safety Run-In Results for a Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Invited. Society for Neuro-Oncology. New Orleans, LA, US.
- 2016. Measuring Mobility and Disability in Patients with Gliomas. Invited. Society for Neuro-Oncology. Phoenix, AZ, US.
- 2015. A Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) in Adults with Recurrent Glioblastoma. Invited. American Society of Clinical Oncology. Chicago, IL, US.
International Presentations
- 2023. ORAL PRESENTER: (CTIM-23 ) Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma. Conference. Society for Neuro-Oncology. Vancouver, CA.
Formal Peers
- 2023. Advancing Clinical Trial Design in Glioblastoma. Visiting. Decatur, GA, US.
- 2015. Fundamentals of Brain Tumors. Invited. Houston, TX, US.
- 2014. Fundamentals of Brain Tumors. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2025 - 2027 |
| Title: | Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP250190 |
| Date: | 2022 - Present |
| Title: | A Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Cabozantinib in Combination with Atezolizumab in Patients with Recurrent Glioblastoma (GBM) |
| Funding Source: | Genentech, Inc |
| Role: | PI |
| Date: | 2022 - Present |
| Title: | A Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Cabozantinib in Combination with Atezolizumab in Patients with Recurrent Glioblastoma (GBM) |
| Funding Source: | Exelixis |
| Role: | PI |
| Date: | 2019 - Present |
| Title: | 2019-0216 GBM AGILE Global Adaptive Trial Master Protocol |
| Funding Source: | Global Coalition for Adaptive Research |
| Role: | PI |
| Date: | 2019 - Present |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Project Leader |
| ID: | P50 CA127001 |
Selected Publications
Peer-Reviewed Articles
- Majd N, Weathers SP, de Groot J. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?. Neuro Oncol 21(11):1344-1345, 2019. e-Pub 2019. PMID: 31515554.
- Kesler SR, Harrison RA, Petersen ML, Rao V, Dyson H, Alfaro-Munoz K, Weathers SP, de Groot J. Pre-surgical connectome features predict IDH status in diffuse gliomas. Oncotarget 10(60):6484-6493, 2019. e-Pub 2019. PMID: 31741712.
- Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, Weathers SP, Demetri GD, Araujo D, Conley AP. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer 7(1):296, 2019. e-Pub 2019. PMID: 31703609.
- Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 145(1):97-105, 2019. e-Pub 2019. PMID: 31456142.
- Acquaye AA, Payén SS, Vera E, Williams LA, Gilbert MR, Weathers SP, Armstrong TS. Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. J Patient Rep Outcomes 3(1):58, 2019. e-Pub 2019. PMID: 31444579.
- Milbury K, Li J, Weathers SP, Mallaiah S, Armstrong T, Li Y, Bruera E, Cohen L. Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. Neurooncol Pract 6(4):311-320, 2019. e-Pub 2019. PMID: 31386042.
- Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther 18(5):991-1000, 2019. e-Pub 2019. PMID: 30926639.
- Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer 112:83-93, 2019. e-Pub 2019. PMID: 30951926.
- Weathers SP, Epner DE. Rookie. J Clin Oncol 37(9):751-753, 2019. e-Pub 2019. PMID: 30742562.
- Hamouda D, Nascimento FA, Weathers SP, Kumar VA. Stroke-like migraine attacks after radiation therapy (SMART) syndrome. Arq Neuropsiquiatr 77(3):215, 2019. e-Pub 2019. PMID: 30970135.
- Milbury K, Li J, Weathers SP, Shih T, Malliaha S, Li Y, Cohen L. A research protocol for a pilot, randomized controlled trial designed to examine the feasibility of a dyadic versus individual yoga program for family caregivers of glioma patients undergoing radiotherapy. Pilot Feasibility Stud 5:95, 2019. e-Pub 2019. PMID: 31367462.
- Milbury K, Mallaiah S, Mahajan A, Armstrong T, Weathers SP, Moss KE, Goktepe N, Spelman A, Cohen L. Yoga Program for High-Grade Glioma Patients Undergoing Radiotherapy and Their Family Caregivers. Integr Cancer Ther 17(2):1534735417689882, 2018. e-Pub 2018. PMID: 28150503.
- Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget 7(43):69466-69478, 2016. e-Pub 2016. PMID: 27579614.
- Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18(10):1357-66, 2016. e-Pub 2016. PMID: 27370400.
- Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WK, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol 129(3):487-94, 2016. e-Pub 2016. PMID: 27406589.
- Gatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol 5(1):11-26, 2016. e-Pub 2016. PMID: 26670466.
- Weathers SP, Gilbert MR. Current challenges in designing GBM trials for immunotherapy. J Neurooncol 123(3):331-7, 2015. e-Pub 2015. PMID: 25577401.
- Weathers SP, Kotagal V, Bohnen NI, Chou KL. Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. Parkinsonism Relat Disord 20(1):13-6, 2014. e-Pub 2014. PMID: 24070538.
Review Articles
- Weathers SS, Gilbert MR. Toward Personalized Targeted Therapeutics: An Overview. Neurotherapeutics 14(2):256-264, 2017. e-Pub 2017. PMID: 27995437.
- Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB. Tumor Vaccines for Malignant Gliomas. Neurotherapeutics 14(2):345-357, 2017. e-Pub 2017. PMID: 28389997.
- Weathers SP, de Groot J. VEGF Manipulation in Glioblastoma. Oncology (Williston Park) 29(10):720-7, 2015. e-Pub 2015. PMID: 26470893.
- Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep 14(5):443, 2014. e-Pub 2014. PMID: 24652451.
- Weathers SP, Gilbert MR. Advances in treating glioblastoma. F1000Prime Rep 6:46, 2014. e-Pub 2014. PMID: 24991423.
Abstracts
- Dasgupta P, Lin H, Kumar G, Soomro Z, Ayala M, Parra E, Weathers S, Lang F, Bhat K, de Groot J, Majd N. Molecular and Clinical Determinants of Response to Immunotherapy in High-Grade Glioma. 2025 Annual Meeting for the Society for Neuro-Oncology 27(Supp_5):v28, 2025. e-Pub 2025.
- Majd N, Dagher S, Wang S, Salvatierra M, Solis Soto L, Lius S, Yeboa N, Weathers S, Gachimova E, Wathoo C, Kamiya-Matsuoka C, O'Brien B, Patel A, Puduvalli V, Wintermark M. Phase I Trial of Peposertib (DNA-PK Inhibitor) Plus Radiation in Newly Diagnosed MGMT-Unmethylated Glioblastoma, Updated Clinical, Radiographic, and Biomarker Outcomes. 2025 Annual Meeting for the Society of Neuro-Oncology 27(Supplement_5):v152, 2025. e-Pub 2025.
- Highsmith K, Isakadze M, Adnan A, Beckham T, Weathers S. A Single-Center Experience of Elderly Glioblastoma Treatment – Standard vs Hypofractionated Radiotherapy with Concurrent Temozolomide. 2025 Annual Meeting for the Society of Neuro-Oncology 27(Supp_5):v387, 2025. e-Pub 2025.
- Alfattal R, Weathers S, Dasgupta P, Ballester LY, Gubbiotti MA. An Institutional Experience with the DNA Methylation Class High Grade Glioma with Pleomorphic and Pseudopapillary Features. 2025 Annual Meeting of the American Association of Neuropathologists 84(6):517. e-Pub 2025.
- Patel AD, Aaroe A, Kamiya-Matsuoka C, Lin R, Majd N, O'Brien BJ, Patel CB, Weathers S, Puduvalli VK. Dual Targeting of VEGF and PD-1. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
- Kamiya-Matsuoka C, Weathers S, Knight S, Hanna T, Langlands J, Brown D, Puduvalli V. RELA Fusion-Positive Ependymoma, Diffuse Midline Glioma and Grade 4 IDH Mutant Astrocytoma Treated with VAL-083 Under Expanded Access. 2024 Annual Meeting for the Society for Neuro-Oncology 26(Suppl_8):viii113, 2024. e-Pub 2024.
- Kamiya-Matsuoka C, Weathers S, Harrison R, Majd N, Aaroe A, Knight S, Hanna T, Patel C, Langlands J, Brown D, Puduvalli V. VAL-083 In Patients with Recurrent Glioblastoma Treated Under Expanded Access Program. 2024 Annual Meeting for the Society for Neuro-Oncology 26(Suppl_8):viii113-viii114, 2024. e-Pub 2024.
- Majd N, Liu J, Yeboa N, Wang S, Weathers S, Yuan Y, Gachimova E, Wathoo C, Kamiya-Matsuoka C, O'Brien BJ, Aaroe A, Patel C, Patel A, Dagher S, Wintermark M, Ferguson S, Puduvalli V, Raleigh D, de Groot J. Phase I Clinical Trial of Peposertib Plus Radiotherapy in Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma. 2024 Annual Meeting for the Society for Neuro-Oncology 26(Suppl_8):viii119, 2024. e-Pub 2024.
- Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin ME, Majd N, Brown D, Langlands J, Schwartz R, Knight S, Puduvalli V, de Groot J, O'Brien BJ. Assessment of Molecular Alternatives in Newly Diagnosed GBM MGMT-Unmethylated Patients Treated with VAL-083. 2024 Annual Meeting for the Society for Neuro-Oncology 26(Suppl_8):viii114, 2024. e-Pub 2024.
- Mellinghoff IK, Cloughesy T, Alexander B, Berry DA, Buxton M, Cavenee W, Colman H, de Groot J, Ellingson BM, Gordon GB, Lassman AB, Lim M, Khasraw M, Perry J, Sulman EP, Weller M, Wen P, Yung WK, Berry N, Graves T, Detry M, Hyddmark EMV, Johnsson A, Kling H, McGlothlin A, Powell A, Untch S, Aquilanti E, Blondin N, Boulmay B, de la Fuente M, Drappatz J, Jordan J, Kaley TJ, Lobbous M, Mikkelsen T, Newton H, Owen S, Peters K, Schiff D, Sherman W, Weathers S, Youssef M, Friend J, Lee E. Evaluation of Paxalisib in GBM AGILE Phase 3 Registration Platform Trial for Newly Diagnosed and Recurrent Glioblastoma. 2024 Annual Meeting for the Society for Neuro-Oncology 26(Suppl_8):viii1, 2024. e-Pub 2024.
- Nelson BE, Roszik J, Barreto CM, Nardo M, hmed J, Campbell E, Johnson A, Piha-Paul SA, Glitza IC, Weathers S, Cabanillas ME, Javle MM, Meric-Bernstam F, Subbiah V. RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study. Journal of Clinical Oncology 41(16_suppl):3105, 2023. e-Pub 2023.
- Gregory T, Knight S, Aaroe A, O'Brien BJ, Patel CB, Weathers SS, Majd N, Puduvalli VK, Kamiya Matsuoka C. Analysis of tumor progression among patients with glioma after COVID-19 infection. Journal of Clinical Oncology 41(16_suppl):2041, 2023. e-Pub 2023.
- Kamiya Matsuoka C, Weathers S, Harrison RA, Majd NK, Aaroe AE, Knight S, Hanna T, Gregory TA, Langlands J, Brown D, Puduvalli VK. VAL-083 in patients with recurrent glioblastoma treated under expanded access program. Cancer Research 83(8_Supplement), 2023. e-Pub 2023.
- Weathers SP, Zhu H, Knafl M, Damania A, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin ME, Penas-Prado M, Mjad N, Yung WKA, O'Brien BJ, Wistuba II, Futreal A, Wargo JA, Ajami NJ, Woodman SE, de Groot JF. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. 2022 ASCO Annual Meeting 40(16_Suppl), 2022. e-Pub 2022.
- Milbury K, Li J, Weathers S, Silva R, Snyder S, Li Y, Lorenzo C. Yoga Therapy as a Supportive Care Strategy for Family Caregivers of High Grade Glioma Patients: Results of 3-Arm Pilot Randomized Controlled Trial. Neuro-Oncology 23(Suppl_6):vi186, 2021. e-Pub 2021.
- O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, An S, Lopez L, de Groot J. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 23(Suppl_6):vi65, 2021. e-Pub 2021.
- Weathers SP, Knafl M, Parra E, Hernandez S, Solis L, Sanchez Espiridion B, Wistuba I, Futreal A, Maru D, Kamya-Matsuoka C, Harrison R, Joseph V, Yun C, Darbonne W, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, Woodman S, de Groot J. Biomarker Immune Correlates in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Neuro-Oncology 23(Suppl_6):vi49, 2021. e-Pub 2021.
- Ou A, Harrison R, Liu D, Naqvi M, Naqvi SM, O'Brien B, Weathers SP, de Groot J, Bruera E. QOLP-11. Quality of End-of-Life Care in Patients with High Grade Gliomas. Neuro-Oncology 22((suppl 2)):ii177, 2020. e-Pub 2020.
- Aaroe A, Dono A, Youssef M, Alfaro-Munoz K, Weathers SP, O'Brien B, Majd N, Harrison R, Loghin M, Soomro Z, Wiliford G, Fuller G, Yung WKA, Yeboa D, Esquenazi Y, Ballester LY, de Groot J, Kamiya-Matsuoka C. PATH-05. A Retrospective Study of Treatment Strategies and Outcomes in WHO Grade II and III Isocitrate Dehydrogenase (IDH) Wild-Type Astrocytoma. Neuro-Oncology 22((suppl 2)):ii64-ii65, 2020. e-Pub 2020.
- O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot J. CTNI-72. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 22((suppl 2)):ii59, 2020. e-Pub 2020.
- Weathers SP, Kamiya-Matsuoka C, Harrison R, Liu D, Sanqui, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, de Groot J. CTIM-11. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 22((suppl 2)):ii35, 2020. e-Pub 2020.
- Aaroe A, Team D, Harrison R, Majd N, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, de Groot J, Woodman K. COVD-30. A Snapshot of the Impact of COVID-19 on Patients with Nervous System Tumors. Neuro-Oncology 22((suppl 2)):ii27, 2020. e-Pub 2020.
- Weathers S, Penas-Prado M, Banerjee PP, Bdiwi M, Shaim H, AlsulimanA, Shanley M, Long J, groot D, JF, O’Brien BJ, Majd N, Harrison RA, Kamiya Matsuoka C, Fuller GN, Chi L, Rao G, Lang FF, Shpall EJ, Rezvani K, Hemiberger AB. A Phase I/II Clinical Trial of Autologous CMV-Specific T Cells in Glioblastoma (GBM) Patients to Reveal a Lack of Immune Effector Function. 2020 ASCO Annual Meeting 38(15_suppl), 2020. e-Pub 2020.
- Weathers S, Kamiya Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd N, Yung WK, O’Brian BJ, de Groot JF. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). 2020 ASCO Annual Meeting 38(15_suppl 15), 2020. e-Pub 2020.
- Majd N, Mastall M, Hess K, Fuller G, Alfaro-Munoz K, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandbuerg SI, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Weathers SP, Harrison R, de Groot J, Penas-Prado M. Characterization of Adult Medulloblastoma: A Retrospective Review of 200 Patients at MD Anderson Cancer Center. Neuro-Oncology 21((suppl 6)):vi231-vi232, 2019. e-Pub 2019.
- Milbury K, Weathers SP, Durrani S, Li Y, Carmack C, Buruera E. Acceptability randomized controlled trial a couples-based mind-body intervention for patients with high grade glioma and their partners. Neuro-Oncology 21((suppl 6)):vi205, 2019. e-Pub 2019.
- O’Brien B, Penas-Prado M, Kamiya C, Weathers SP, Yung WK, Loghin M, Harrison RA, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot JF. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-unmethylated, Bevacizumab-naïve Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 21((suppl 6)):vi14–vi15, 2019. e-Pub 2019.
- Metrus N, Kamiya C, Weathers SP, Seligman C, O'Brien B. Improvement of Leptomeningeal Disease Following Infectious Meningitis. Neuro-Oncology 21((suppl 6)):vi59, 2019. e-Pub 2019.
- Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot J, O'Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Neuro-Oncology Advances 1(suppl_1):i8, 2019. e-Pub 2019.
- Trevino CR, Weathers SP, Alfaro-Munoz K, Hallatt G, Williford GL, Park M, Liu DD, Overeen T, Mandel JJ, de Groot JF. Retrospective Review for Outcomes of IDH Mutant, 1p/19q Co-deleted Gliomas Based on Initial Treatment. Journal of Clinical Oncology 37(suppl), 2019. e-Pub 2019.
- Harrison RA, Liu R, Rao V, Petersen M, Dyson H, Weathers SS, Alfaro-Munoz K, de Groot JF, Kesler S. Evaluating the Capacity of Connectome Analysis to Predict Survival in High-Grade Astrocytoma. Journal of Clinical Oncology 37(suppl_15), 2019. e-Pub 2019.
- Hamouda D, Jazebi N, Weathers SP. Sequelae of Cranial Irradiation: Stroke-like Migraine Attacks After Radiation Therapy (SMART) Syndrome. Neurology 92((suppl 15)), 2019. e-Pub 2019.
- Metrus NR, Harrison RA, Ferguson S, Weathers SP. Isolated CNS Blastic Plasmacytoid Dendritic Cell Neoplasm in a Patient with AML. Neurology 92((suppl 15)), 2019. e-Pub 2019.
- Kamiya Matsuoka C, Metrus N, Weathers S, Ross J, Shaw KR, Penas-prado M, Loghin ME, Alfaro-Munoz K, O'Brien BJ, Harrison R, Sadighi Z, Majd N, Yung WK, Meric-Bernstam F, Hambardzumyan D, de Groot J. Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline Mutations?. Annals of Oncology 30((suppl 5)):v143-v158, 2019. e-Pub 2019.
- Mastall M, Majd N, Fuller G, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandberg D, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weathers S, Harrison R, de Groot J, Penas-Prado M. Characterization of Adult Medulloblastoma Patients at Recurrence: Retrospective Review of the MD Anderson Cancer Center Experience. Neuro-Oncology 20((suppl 6)):vi239, 2018. e-Pub 2018.
- de Groot J, Penas-Prado M, Mandel J, O’Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse J, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger A. Window-of-Opportunity Clinical Trial of Pembrolizumab in Recurrent Glioblastoma Patients. Neuro-Oncology 20((suppl 6)):vi2, 2018. e-Pub 2018.
- Weathers S, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O’Brien B, Harrison R, Yung WK, Penas-Prado M, de Groot J. Safety Run-In Results for a Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 20((suppl 6)):vi9–vi10, 2018. e-Pub 2018.
- Barbara O’Brien B, de Groot J, Kamiya-Matsuoka C, Weathers S, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naïve Recurrent Glioblastoma. Neuro-Oncology 20((suppl 6)):vi17, 2018. e-Pub 2018.
- Metrus N, Daher A, Harrison R, Majd N, Maraka S, Nam J, Trevino C, Weathers S, O’Brien B, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WK, de Groot J, Penas-Prado M. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Neuro-Oncology 20((suppl 6)):vi141, 2018. e-Pub 2018.
- Penas-Prado M, Weathers S, Zhou S, Kamiya-Matsuoka C, O’Brien B, Loghin M, Harrison R, Pei B, Ictech S, Hunter K, Yung WK, de Groot J, Shpall EJ, Heimberger A, Rezvani K. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Neuro-Oncology 20((suppl 6)):vi2–vi3, 2018. e-Pub 2018.
- Mastall M, Majd N, Fuller G, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandberg D, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weathers S, Harrison R, de Groot J, Penas-Prado M. Adult Medulloblastoma: Analysis of Use of Chemotherapy in Clinical Practice. Neuro-Oncology 20((suppl 3)):iii325, 2018. e-Pub 2018.
- Kamia Matsuoka C, Metrus NR, Shaw KR, Penas-Prado M, Weathers, SS, Loghin ME, Alfaro-Munoz K, Yuan Y, O'Brien BJ, Harrison, RA, Yung, WK, Meric-Bernstam F, Groot D, JF. The Natural Course of Hypermutator Gliomas. Journal of Clinical Oncology 36(suppl), 2018. e-Pub 2018.
- Penas-Prado M, Rezvani K, Weathers SS, Zhou S, Kamiya Matsuoka C, O'Brien BJ, Loghin ME, Harrison RA, Pei BL, Ictech S, Hunter K, Yung WK, de Groot JF, Shpall EJ, Heimberger AB. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma. ASCO 36(15_suppl), 2018. e-Pub 2018.
- de Groot JF, Penas-Prado M, Mandel JJ, O'Brien BJ, Weathers, SS, Zhou S, Hunter K, Alfaro-Munoz K, Fuller GN, Huse J, Rao G, Weinber JS, Prabu SS, Ferguson SD, Yuan Y, Vence LM, Allison JP, Sharma P, Heimberger AB. Window-of-Opportunity Clinical Trial of a PD-1 Inhibitor in Patients with Recurrent Glioblastoma. Journal of Clinical Oncology 36((suppl 15)), 2018. e-Pub 2018.
- Abrol S, Kotrotsou A, Hassan A, Elshafeey N, Agarwal A, Hassan I, Idris T, Salek K, Farid N, McDonald C, Weathers SP, Bahrami N, Bergamaschi S, Elakkad A, Alfaro-Munoz K, Moron F, Huse J, Weinberg J, Heimberger A, Sawaya R, Kumar A, de Groot JF, Law M, Zinn P, Colen R. Radiomic Analysis of Pseudo-Progression Compared to True Progression in Glioblastoma Patients: A Large-Scale Multi-Institutional Study. Journal of Clinical Oncology 19(suppl_6):vi162-vi163, 2017. e-Pub 2017.
- Kamiya-Matsuoka C, Shaw K, Loghin M, Penas-Prado M, O'Brien B, Weathers S, Alfaro-Munoz K, Yung WK, de Groot J. The Natural Course of Hypermutator Gliomas. Neuro-Oncology 19((suppl 6)):vi179, 2017. e-Pub 2017.
- Milbury K, Lopez G, Weathers S, Eto O, Li J, Cohen L. Illness Communication, Spousal Support and Symptom Burden in Couples Coping With Glioma. Neuro-Oncology 19((suppl 6)):vi203, 2017. e-Pub 2017.
- Milbury K, Mallaiah S, Mahajan A, Armstrong T, Weathers S, Li J, Cohen L. Feasibility Randomized Controlled Trial of a Dyadic Yoga Program for Patients with Brain Tumors Undergoing Radiotherapy and Their Family Caregivers. Neuro-Oncology 19((suppl 6)):vi205, 2017. e-Pub 2017.
- Zheng S, Wei W, Chen K, Alfaro-Munoz K, Eterovic AK, Shaw K, Mills G, Meric-Bernstam F, Verhaak R, Yung WK, Weathers S, de Groot J. Deep Panel Sequencing of a Prospectively Collected Glioma Cohort. Neuro-Oncology 19((suppl 6)):vi98-vi99, 2017. e-Pub 2017.
- Gatson N, Brimley C, Rao G, Chi L, Prabhu S, Weathers S. Role for Laser Interstitial Thermal Therapy (LITT) to Manage Progressed Glioblastoma During Pregnancy. Neuro-Oncology 19((suppl 6)):vi269, 2017. e-Pub 2017.
- Nam J, Harrison RA, Weathers SS, Pillainayagam C, de Groot JF, Kamiya Matsuoka C, Yung WK, Li J, Ferguson SD, O'Brien BJ. Association of Clinical Phenotype and Treatment History with Survival in Adult Brainstem Glioblastoma. Journal of Clinical Oncology 35(15):Suppl, e13539-e13539, 2017. e-Pub 2017.
- Gatson NN, Pillainayagam C, Rao G, Chi TL, Prabhu S, Weathers SP. Laser Interstitial Thermal Therapy (LITT) to Manage Progressed Glioblastoma During Pregnancy. Neuro Oncol 18((suppl 6)), 2016. e-Pub 2016.
- Armstrong T, Payen S, Vera E, Acquaye A, Alfaro-Munoz K, Nielsen D, Penas-Prado M, Weathers SP, O'Brien B, de Groot J. The Impact of Molecular Diagnostics on Function and Symptom Burden in Glioma Patients. Neuro Oncol 18((suppl 6)), 2016. e-Pub 2016.
- Weathers SP, Bolanos EV, Payen S, Acquaye A, Ng A, Weinberg J, Brown P, Armstrong T. Measuring Mobility and Disability in Patients with Gliomas. Neuro Oncol 18((suppl 6)), 2016. e-Pub 2016.
- Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune Checkpoint Blockade as a Potential Therapeutic Target: Surveying CNS Malignancies. Neuro Oncol 18(10):1357-66, 2016. e-Pub 2016. PMID: 27370400.
- Mammoser AG, Weathers SP, Seewald NJ, Taylor JMG, Junck L. Primary CNS Lymphoma; A Review of the University of Michigan Experience 2004-2013. Journal of Clinical Oncology(33):(suppl;abstr e13012), 2015. e-Pub 2015.
- Weathers SP, Han SX, Liu DD, Conrad CA, Gilbert MR, Loghin BO, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Yung WK, de Groot JF. A Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) in Adults with Recurrent Glioblastoma. Journal of Clinical Oncology(33):(suppl;abstr 2005), 2015. e-Pub 2015.
Book Chapters
- Weathers, S, Ou, A. Treatment and Prevention of Venous Thromboembolism. In: Brain Tumors: A Pocket Guide. 1. Springer Cham, 165-176, 2023.
- Weathers SP, Epner DE. The Backstory is the Real Front Story. In: Empathy: Real Stories to Inspire and Enlighten Busy Clinicians. McGraw Hill Publisher, 191-204, 2022.
- Weathers SP, O'Brien B, Aaroe A, Yeboa D, Prabhu S, de Groot J. Tumors of the Central Nervous System. In: The MD Anderson Manual of Medical Oncology. Fourth Edition. McGraw Hill LLC, 2022.
- Ferguson SD, Weathers SP, Heimberger AB. Chapter 34: Immune Checkpoint Blockade in Glioma. In: Oligodendroglioma: Clinical Presentation, Pathology, Molecular Biology, Imaging, and Treatment. 1st. Elsevier Inc./Academic Press, 387-396, 2019.
- Harrison RA, Nam JY, Weathers SP, DeMonte F. Intracranial dural, calvarial, and skull base metastases. In: Handb Clin Neurol, 205-225, 2018.
- Weathers SP, O'Brien BJ, de Groot JF. Chapter 40: Tumors of the Central Nervous System. In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw-Hill Education, 826-856, 2016.
- Weathers SP, O'Brien BJ, de Groot JF, Yung WK. Chapter 18: Targeted Therapy in Solid Tumors: Brain. In: Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, 179-189, 2015.
Patient Reviews
CV information above last modified July 22, 2026